Evidence map›Paper›PMID 39153970›Full record

ArticleDiagnostic pathology2024

Prognostic and immune infiltration implications of SIGLEC9 in SKCM.

Peipei Yang, Yunhui Jiang, Rong Chen, Junhan Yang, Mengting Liu, Xieping Huang, Ganglin Xu, Rui Hao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diagnostic pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Peipei Yang *Department of Dermatology, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China.
Yunhui Jiang *Department of Pathology, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China.
Rong Chen *Department of Clinical Laboratory, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China.
Junhan YangDepartment of Dermatology, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China.
Mengting LiuDepartment of Dermatology, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China.
Xieping HuangDepartment of Dermatology, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China.
Ganglin XuDepartment of Dermatology, Jingmen People'S Hospital &, Jingchu University of Technology Affiliated Central Hospital, Jingmen, 448000, China. jmganglinxu@163.com.
Rui HaoDepartment of Oncology, Xiangyang Central Hospital, Affiliated Hospital of Hubei University of Arts and Science, Xiangyang, 441021, China. 825993347@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The occurrence and progression of skin cutaneous melanoma (SKCM) is strongly associated with immune cells infiltrating the tumor microenvironment (TME). This study examined the expression, prognosis, and immune relevance of SIGLEC9 in SKCM using multiple online databases. Analysis of the GEPIA2 and Ualcan databases revealed that SIGLEC9 is highly expressed in SKCM, and patients with high SIGLEC9 expression had improved overall survival (OS). Furthermore, the mutation rate of SIGLEC9 in SKCM patients was found to be 5.41%, the highest observed. The expression of SIGLEC9 was positively correlated with macrophages, neutrophils and B cells, CD8 + T cells, CD4 + T cells, and dendritic cells, according to TIMER. Based on TCGA-SKCM data, we verified that high SIGLEC9 expression is closely associated with a good prognosis for SKCM patients, including overall survival, progression-free interval, and disease-specific survival. This positive prognosis could be due to the infiltration of immune cells into the TME. Additionally, our analysis of single-cell transcriptome data revealed that SIGLEC9 not only played a role in the normal skin immune microenvironment, but is also highly expressed in immune cell subpopulations of SKCM patients, regulating the immune response to tumors. Our findings suggest that the close association between SIGLEC9 and SKCM prognosis is primarily mediated by its effect on the tumor immune microenvironment.

Indexed as

Biomarkers, TumorMelanomaSkin NeoplasmsTumor MicroenvironmentAntigens, CDCutaneous Malignant MelanomaHumansLymphocytes, Tumor-InfiltratingPrognosisSialic Acid Binding Immunoglobulin-like LectinsAntigens, CDBiomarkers, TumorSialic Acid Binding Immunoglobulin-like LectinsSIGLEC9 protein, humanSIGLEC9Single cellSkin cutaneous melanomaTumor infiltrating immune cellsTumor microenvironment

Identifiers

PMID39153970
PMCPMC11330613

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.